Prompt® is a lab-developed test (LDT) performed under CLIA license at the San Diego Blood Bank that can be sold publicly.

Prompt is based on a decade of work and hundreds of millions of dollars in research funding. It has been validated in over 10,000 men in some of the most important prostate cancer trials ever performed and indirectly validated in over 100,000 men. The test incorporates the genetic information from dozens of prostate cancer-risk associated SNPs. Using population-based analyses, the test reports how many men (out of 100) with a given genetic score would go on to develop prostate cancer. With those findings, physicians and patients together can decide whether to pursue prostate cancer screening.

Prompt Prostate Genetic Score has been evaluated in some of the most important prostate cancer trials ever conducted:

The Randomized Prostate Cancer Prevention Trial1 Comparing Finasteride to Placebo

  • The largest prostate cancer prevention trial ever performed
  • Men over the age of 55 with normal rectal examinations and PSAs less than 3 ng/ml at study entry
  • The placebo arm of this study allows for the direct comparison of various biomarkers

The REDUCE Randomized Chemoprevention Trial2 Comparing Dutasteride to Placebo

  • Men over the age of 50 with PSA between 2.5 and 10 and a negative prostate biopsy within six months of study entry
  • The placebo arm of this study allows for the direct comparison of various biomarkers

The Randomized PLCO Study3

  • The largest American study assessing the possible benefit of PSA-based prostate cancer screening
  1. Kilpelainen TP, Tammela TL, Roobol M, Hugosson J, Ciatto S, Nelen V, et al. False-positive screening results in the European randomized study of screening for prostate cancer. European journal of cancer (Oxford, England : 1990). 2011;47(18):2698-705.
  2. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. The New England journal of medicine. 2010;362(13):1192-202.
  3. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostatecancer screening trial. The New England journal of medicine. 2009;360(13):1310-9.
×